Over-the-counter nasal spray cuts COVID cases by two-thirds in clinical trial

By Newsroom,  published 14 September 2025 at 17h07, updated on 14 September 2025 at 17h08.

ADN

A non-prescription nasal spray has demonstrated significant effectiveness in a clinical trial, lowering COVID-19 cases by approximately 66 percent. The results suggest a promising new tool in the fight against the ongoing pandemic.

TL;DR

  • Nasal spray azelastine may lower COVID-19 infection rates.
  • Widely available over-the-counter in 70+ countries.
  • Larger studies needed before widespread recommendation.

    • Unexpected Ally in the Fight Against COVID-19

    For decades, allergy sufferers have relied on a nasal spray containing azelastine, available without prescription in more than 70 countries. Traditionally used to soothe symptoms of hay fever, this humble remedy has now drawn the scientific spotlight for an entirely different reason: its potential to reduce COVID-19 infection rates.

    Remarkable Clinical Findings

    A recent study, led by Professor Robert Bals at the University of Saarland in Germany, placed nearly 450 participants into two groups—one using the azelastine spray three times daily, the other receiving a placebo. After an eight-week trial period, researchers observed that only 2.2% of those given azelastine contracted SARS-CoV-2, compared to 6.7% in the placebo group. The difference? According to Prof. Bals, individuals using the active spray experienced roughly three times fewer infections. Notably, researchers also recorded fewer symptomatic cases and a surprising decline in other respiratory infections such as rhinovirus—a finding that hints at broader applications than initially imagined.

    Azelastine’s Accessibility and Cautionary Notes

    Given its established safety record and ready availability, azelastine might seem like an obvious addition to existing pandemic measures—especially for vulnerable groups or travelers facing heightened exposure risks. Here’s what makes this substance stand out:

  • No prescription required in most countries.
  • Well-documented safety from decades of use.
  • Plausible benefit against multiple respiratory viruses.

    • Still, even with these encouraging signals, scientists urge restraint. While initial results are promising, asserting that azelastine alone can prevent illness would be premature. The medical community is clear: further evidence is essential before any sweeping recommendations are made.

    The Road Ahead for Research

    Questions remain about precisely how this medication interferes with viral activity. Current hypotheses suggest it may block replication of SARS-CoV-2 or prevent its attachment in nasal passages—a key entry point for infection. Yet such theories need validation through larger and more diverse trials, particularly among populations most at risk.

    In short, while azelastine’s role is far from fully defined, its surprising effect against COVID-19 offers a glimmer of hope—and a strong incentive for continued investigation into accessible pandemic tools.